v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows used in operating activities:    
Net loss $ (10,793) $ (4,834)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 59 90
Share-based compensation 177 220
Amortization of acquired in-process R&D asset 4,947 0
Warrant and derivative liabilities issuance cost 113 0
Amortization of discount and issuance costs of convertible note 940 0
Change in fair value of warrant and derivative liabilities (525) 0
Exchange rate fluctuations (3) (7)
Changes in assets and liabilities:    
Trade receivables, net 474 839
Prepaid expenses and other assets (256) (271)
Operating lease right-of-use assets 53 91
Inventories (624) (86)
Trade payables 1,228 (806)
Employees and payroll accruals (157) (158)
Deferred revenues 21 (72)
Operating lease liabilities (46) (261)
Other liabilities 717 (238)
Net cash used in operating activities (3,675) (5,493)
Cash flows used in investing activities:    
Purchase of property and equipment 0 (5)
Cash acquired in connection with the acquisition of Oratech [1] 6,500 0
Net cash provided by (used in) investing activities 6,500 (5)
Cash flows from financing activities:    
Issuance of ordinary shares in a “registered direct” offering, net of issuance expenses in the amount of $529 [2] 0 4,471
Net proceeds from issuance of Additional Notes [3],[4] 1,025 0
Net proceeds from issuance of New Notes [4],[5] 1,955 0
Net proceeds from issuance of derivative liabilities [4],[5] 1,820 0
Net proceeds from issuance of warrant liabilities [4],[5] 1,622 0
Net cash provided by financing activities 6,422 4,471
Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash 3 7
Increase (Decrease) in cash, cash equivalents, and restricted cash 9,250 (1,020)
Cash, cash equivalents, and restricted cash at beginning of period 2,579 7,108
Cash, cash equivalents, and restricted cash at end of period 11,829 6,088
Supplemental disclosures of non-cash flow information    
Classification of inventory to property and equipment, net 45 5
Recognition of warrant liability upon issuance of New Notes 1,175 0
Recognition of derivative liability associated with New Notes 1,317 0
Expenses related to offerings not yet paid [2] 0 250
Supplemental cash flow information:    
Cash and cash equivalents 11,422 5,728
Restricted cash 407 360
Total Cash, cash equivalents, and restricted cash $ 11,829 $ 6,088
[1] Represents cash acquired in connection with the acquisition of Oratech from Oramed Pharmaceuticals Inc., a related party, of $6,500.
[2] See Note 8f to the condensed consolidated financial statements.
[3] Represents proceeds from issuance of Additional Notes to Oramed Pharmaceuticals Inc., a related party, of $1,025 for the three months ended March 31, 2026.
[4] See Note 9 to the condensed consolidated financial statements.
[5] Includes proceeds from issuance of New Notes, derivative liabilities and warrant liabilities to Oramed Pharmaceuticals Inc., a related party, of $4,397 for the three months.